

Paola Cristina Ceratto¹, Maiara Vanusa Guedes Ribeiro¹, Renata Calciolari Rossi e Silva² and Debora Tavares de Resende e Silva^{3*}

¹Degree in nursing from the Federal University Southern Frontier, Brazil

²Professor in University of Oeste paulista, PhD in Health Science, Brazil

³Professor in Federal University Fronteira Sul, PhD in Health Science, Brazil

Dates: Received: 17 June, 2015; Accepted: 24 February, 2016; Published: 25 February, 2016

***Corresponding author:** Debora Tavares de Resende e Silva, PhD. Federal University Fronteira Sul – Campus Chapecó/SC. Rua General Osorio, 413D. CEP: 89802-265. Caixa Postal 181. Bairro Jardim Italia, Chapeco, Santa Catarina, Brazil. E-mail: deboratavares.silva@hotmail.com

www.peertechz.com

Keywords: Vitamin D; Chronic kidney Disease; Mortality

Mini Review

Implications of Vitamin D Deficiency in Chronic Kidney Disease - A Systematic Review

Abstract

Vitamin D presents interesting pleiotropic effects for the CKD patient (effect and anti-inflammatory properties). Patients with chronic kidney disease (CKD) have impaired endothelial function and the Vitamin D and its analogs may play a role in regulation of endothelial function and inflammation. Therefore, it is increasingly observed that CKD is characterized by a state of chronic inflammation that appears to be linked to oxidative stress, endothelial dysfunction and vascular calcification. Previous studies have shown that vitamin D administration in chronic renal failure patients produces therapeutic effects suggesting an inverse relationship between the presence of 25-hydroxyvitamin D [25 (OH) D] and inflammatory biomarkers. It is emphasized so the importance of proper maintenance of the vitamin D status, since it plays an important role in the management of inflammation and immunity, contributing to the reduction of morbidity and mortality in patients with CKD. In addition there is cumulative evidence showing the low level of vitamin D associations with the development and progression of chronic kidney disease, cardiovascular complications and high mortality.

Chronic Kidney Disease (CKD)

Chronic Kidney Disease (CKD), considered the new epidemic of the twenty-first century [1], it is a clinical syndrome characterized by a significant reduction, slow, gradual and progressive renal excretory function, endocrine and metabolic. Its incidence is increasing and has high morbidity and mortality rates even in the pre-dialysis phase. This syndrome affects hydric metabolism, electrolyte and basic acid metabolism. So, reflected in changes in the metabolism of macronutrients, providing situations hyper catabolic, pro-inflammatory and pro-oxidative [2]. In 2013 census, which was conducted by the Brazilian Society of Nephrology (SBN), it was found that about 15 million Brazilians have CKD at some of its stages. Data indicate that 100 397 000 patients received renal replacement therapy in the same year. The number may even be higher as the elderly, obese, diabetic, hypertensive or people with familiar historical account for 52 million people in the country [3].

High mortality rates have been observed between individuals with CKD many authors state that this fact is a result of complications arising from deterioration in renal function and uremia [4-6]. The complications most commonly found in these individuals are abnormalities of the immune system. The consequent increased risk of infection [7], anemia, disturbance of mineral metabolism, exacerbation of oxidative stress [6], systemic inflammation due to repeated hemodialysis (HD) that lead to activation / production of white blood cells, cytokines [7] and C-reactive protein (CRP) [9].

Inflammation and CKD

In recent years, chronic inflammation has become recognized as a major culprit in a range of disease states such as cardiovascular disease, obesity, diabetes, malnutrition and even aging. Therefore, it is increasingly observed that CKD is characterized by a state of chronic

inflammation that appears to be linked to oxidative stress, endothelial dysfunction and vascular calcification [10].

Inflammation is a physiological process in response to different stimuli and infections, physical-chemical and antigenic changes or traumatic damage. The inflammatory response needs to be precisely regulated, since deficiencies or excesses of this response are directly related to mortality and morbidity. In this context, there is evidence activation of the immune system in early and late stages of CKD. Moreover, some studies suggest a negative relationship between circulating levels of mediators of inflammation and disease stage. It is also known that in patients with CKD terminal or not, the presence of inflammation is an independent predictor of mortality [11].

The chronic inflammatory process affects 40-50% of chronic renal [8], characterized by the infiltration of inflammatory cells into the glomeruli and tubulointerstitial starting the pathogenic cascade that eventually leads to destruction renal parenchyma by tissue fibrosis [12]. Signals from an activated immune system can already be observed in the early stages of CKD, and they predictors of various complications such as accelerated atherosclerosis, vascular calcification, insulin resistance, increased muscle catabolism, appetite loss, bone remodeling and increased vascular permeability peritoneal [13].

The reason for the increased risk of chronic inflammation in these patients appears to be complex [10], however, in recent years it has established the role of uremic toxicity as kitten to the immune response and is responsible for increased plasma concentrations systemic inflammatory biomarkers and vascular, consequent increase in pro inflammatory cytokines [14]. The immunological dysfunction related to uremia is a complex interaction between the systems of innate and adaptive immune system, wherein the immunosuppression and immune activation coexist [7].

The increase in inflammatory mediators was associated with increased oxidative stress and the accumulation of advanced glycation products (AGEs) [5]. AGEs are formed when the aldehyde groups of carbohydrates or ketone reacts with amino acids. In CKD patients, it is possible that AGEs accumulation caused by decreased renal clearance can also promote inflammation. Interestingly, the main causes of death in patients with CKD are related to cardiovascular and infectious diseases, both pathological processes closely related to immune function [14]. C-reactive protein elevation (CRP) and pro inflammatory cytokines are independently associated with all-cause cardiovascular mortality in chronic renal patients, therefore, the determination of CRP and interleukin 6 (IL-6) seems to be the best option for risk stratification [15]. Stressing that understanding the mechanisms behind immune dysfunction that is peculiar to CKD assists in creating strategies for improving the quality of life of this group of patients [15].

Vitamin D

Vitamin D is a fat soluble steroid collection, its active form 1,25-dihydroxyvitamin D (1,25 [OH] 2D) or calcitriol, performs the regulation of the calcium and phosphorus homeostasis in the body [16], by intestinal absorption and bone metabolism [17]. Vitamin D is synthesized in the skin or can be ingested in the diet [18]. The skin produces pro vitamin D (cholecalciferol D3) through the action of ultraviolet rays on the same, but the process involves factors such as age and skin pigmentation, and African descendants and advanced age are independent risk factors for vitamin D deficiency.

After their synthesis, vitamin D binds to proteins and is transported via blood to the liver, which occurs 25 carbon hydroxylation, forming calcidiol or 25-hydroxyvitamin D (25 [OH] D) [20], which is transported to the kidneys and converted to the 1 α -hydroxylase enzyme to its active form, 1,25-dihydroxyvitamin D, or calcitriol (1,25 [OH] 2D). The calcitriol is responsible for the effects of vitamin D on calcium and phosphorus metabolism, stimulating the activity of osteoclasts and regulation of the parathyroid glands [18,21]. Over the last years it has been demonstrated that the kidney is not the only tissue that expresses the 1 α -hydroxylase enzyme [21], may 25 (OH) D is enabled for 1,25 dihydroxyvitamin D (1,25 [OH] 2D) regardless of the kidney [22]. The physiological role of the synthesis of 1,25-dihydro-1,25-dihydroxyvitamin D extra renal D macrophages, osteoblasts, parathyroid cells, and vascular smooth muscle cells, endothelial cells and tissues, such as the pancreas, breast, prostate, colon and is not well understood [21]. However, this location of vitamins production system have been associated with negative regulation of the renin-angiotensin system, suppression of vascular calcification [5], cell proliferation, function, and immune inflammation [22], especially with the secretion of chemokines [23].

The biological functions of vitamin D are carried out by binding with receptors genes for vitamin D (VDR), which are found in many body tissues such as skin [24]. The VDR gene is a factor ligand-dependent transcription, which is activated after its binding to vitamin D or analogues thereof, which under normal physiological conditions, are expressed in significant amounts by the tubular cells [12]. Vitamin D deficiency is common in children and adults, and its adverse effects extend beyond bone and mineral metabolism.

Numerous studies have shown an association with cardiovascular disease, insulin resistance, diabetes, infections and inflammation [19], progression of chronic kidney disease (CKD) and immune system disorders [20,25]. A vitamin D deficiency indicator is calcidiol (25 [OH] D) [20].

Vitamin D and inflammation in CKD

The pro-inflammatory state of end-stage CKD is associated with increased risk of cardiovascular disease and death [26]. Vitamin D deficiency is highly prevalent in individuals with CKD. Vitamin D deficiency is probably an important modifiable risk factor in this population [19], that due to uremic state with the skin are impaired photosynthesis calciferol, loss of appetite, urinary losses of vitamin binding protein D (DBP) and albumin, and decreased vitamin intake due to food restriction [19,20]. Several factors, including increasing age and comorbidities such as diabetes and hypertension have also been frequently associated with low levels of 25-hydroxyvitamin D (25 [OH] D) [27].

There are several mechanisms involved in the reduction of 1,25-dihydroxyvitamin D during the course of CKD, highlighting the reduction of renal mass and consequent decrease in glomerular filtration rate, which limit the interaction of 25-hydroxyvitamin D with 1 α -hydroxylase enzyme and therefore limit the ability of the kidneys to produce 1,25-dihydroxyvitamin D [21]. Another mechanism involved is the loss of the VDR, it still occurs at the beginning of CKD due to renal inflammation. The kidney cell infiltration through the secretory cells of pro inflammatory cytokines are essential in mediating suppression VDR tubular epithelium damaged kidneys. It is also reported that TNF, a major pro-inflammatory mediator and suppresses the VDR expression in various cell types [12]. Currently, the growth of fibroblasts (FGF-23) has been widely related vitamin D deficiency in chronic renal failure patients. FGF-23 is a protein produced in bone stimulated by dietary intake of phosphorus that acts on the kidneys producing phosphaturia and suppressing the expression of 1 α -hydroxylase enzyme, which consequently decreases the production of 1,25-dihydroxyvitamin D (1,25 [OH] 2D) [20].

Previous studies have shown that vitamin D administration in chronic renal failure patients produces therapeutic effects [12,18,19,26], suggesting an inverse relationship between the presence of 25-hydroxyvitamin D [25 (OH) D] and inflammatory biomarkers [26]. This inverse relationship mentioned, leads to reduced levels of CRP [18,19,21,26], IL-8 and TNF- α [21,26] and deletion of calcification inducers such as collagen type I. In addition, the activation of suppressor of calcification, such as GLA matrix protein, osteopontin and osteocalcino [28]. It is also demonstrated increased anti-inflammatory effect mediated by IL-10 [26]. The mechanisms underlying these effects may be related to the preservation of renal tubular integrity and the restoration of the VDR receptors, even in already developed renal lesions [12,18].

The vitamin D is often administered in patients with chronic renal problems to mitigate the detrimental effects on the health of the bone and mineral metabolism [28]. However, as seen, the effect of supplementation of only this will greatly benefit. Importantly, vitamin D administration indiscriminately can generate unwanted effects,

such as increased calcium and phosphate, favoring the development of vascular calcifications. Therefore, new vitamin D analogues have been suggested for substitution of calcitriol [28], due to the fact it has the disadvantage of producing phosphorus and raising serum calcium levels. This effect is caused by increasing intestinal absorption of both electrolytes, since calcium and phosphorus are not properly excreted due to kidney failure [29].

Conclusion

It is emphasized so the importance of proper maintenance of the vitamin D status, since it plays an important role in the management of inflammation and immunity, contributing to the reduction of morbidity and mortality in patients with CKD [23]. There is cumulative evidence showing the low level of vitamin D associations with the development and progression of chronic kidney disease, cardiovascular complications and high mortality.

References

1. Braga FLM, De Arruda LKG, Diniz ADS, Cabral PC, Lemos MDCC, et al. (2013) Disfunção renal e marcadores inflamatórios em hipertensos atendidos em hospital universitário. *Arq Bras Cardiol*.
2. Barbosa ACSCS, Salomon ALR (2012) Resposta inflamatória de pacientes com doença renal crônica em fase pré-dialítica e sua relação com a ingestão protéica. *Com. Ciências Saúde*.
3. Sesso RC, Lopes AA, Thomé FS, Lugon JR, Watanabe Y, et al. (2014) Relatório do Censo Brasileiro de Diálise Crônica 2012. *J Bras Nefrol* 36: 53.
4. Bowry SK, Gatti E (2011) Impact of Hemodialysis Therapy on Anemia of Chronic Kidney Disease: The Potential Mechanisms. *Blood Purif* 32: 210-219.
5. Lee DM, Jackson KW, Knowlton N, Wages J, Alaupovic P, et al. (2011) Oxidative stress and inflammation in renal patients and healthy subjects. *Plos One* 6: E22360.
6. Barberato SH, Gardano SGE, De Souza AM, Costantini CO, Costantini CRF, et al. (2013) Associação entre Marcadores de Inflamação e Aumento do Átrio Esquerdo em Pacientes de Hemodiálise. *Arq Bras Cardiol* 100: 141-146.
7. Tbahriti HF, Meknassi D, Moussaoui R, Messaoudi A, Zemor L, et al. (2013) Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines. *World J Nephrol* 2: 31-37.
8. Bucharles SG, Varela AM, Barberato SH, Pecoits-Filho R (2010) [Assessment and management of cardiovascular disease in patients with chronic kidney disease]. *J Bras Nefrol* 32: 118-125.
9. Bayraktar G, Kurtulus I, Kazancioglu R, Bayramgurler I, Cintan S, et al. (2009) Oral health and inflammation in patients with end-stage renal failure. *Perit Dial Int* 29: 472-479.
10. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, et al. (2005) IL-10, IL-6, and TNF- α : central factors in the altered cytokine network of uremia – the good, the bad, and the ugly. *Kidney Int* 67: 1216-1233.
11. Vianna HR, Soares CMBM, Tavares MS, Teixeira MM, Silva ACS (2011) Inflamação na doença renal crônica: papel de citocinas. *J Bras Nefrol* 33: 351-364.
12. Xiong M, Gong J, Liu Y, Xiang R, Tan X (2012) Loss of vitamin D receptor in chronic kidney disease: a potential mechanism linking inflammation to epithelial-to-mesenchymal transition. *Am J Physiol Renal Physiol* 303: F1107-F1115.
13. Pecoits-Filho R, Sylvestre LC, Stenvinkel P (2005) Chronic kidney disease and inflammation in pediatric patients: from bench to playground. *Pediatr Nephrol* 20: 714-720.
14. Hauser AB, Stingham AE, Kato S, Bucharles S, Aita C, et al. (2008) Characteristics and causes of immune dysfunction related to uremia and dialysis. *Perit Dial Int* 28: S183-187.
15. Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, et al. (2008) Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. *Nephrol Dial Transplant* 23: 2337-2343.
16. Wang C (2013) Role of vitamin D in Cardiometabolic Diseases. *J Diabetes Res* 2013: 243934.
17. Khan H, Kunutsor S, Franco OH, Chowdhury R (2013) Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. *Proceedings of the Nutrition Society* 72: 89-97.
18. Eleftheriadis T, Antoniadi G, Liakopoulos V, Stefanidis I, Galaktidou G (2012) Inverse Association of Serum 25-Hydroxyvitamin D with Markers of Inflammation and Suppression of Osteoclastic Activity in Hemodialysis Patients. *Iran J Kidney Dis* 6: 129-135.
19. Kalkwarf HJ, Denburg MR, Strife CF, Zemel BS, Foerster DL, et al. (2012) Vitamin D deficiency is common in children and adolescents with chronic kidney disease. *Kidney Int* 81: 690-697.
20. Rodríguez Villarreal I, Ortega O, Gallar P, Sánchez M, Callejas R, et al. (2011) Clinical and biochemical characteristics of predialysis patients in terms of 25 hydroxy vitamin D levels. *Nefrología* 31: 185-191.
21. Dusso A, González EA, Martin KJ (2011) Vitamin D in chronic kidney disease. *Best Practice & Research Clinical Endocrinology & Metabolism* 25: 647-655.
22. Ponda MP, Breslow JL (2013) Vitamin D3 Repletion in Chronic Kidney Disease Stage 3: Effects on Blood Endotoxin Activity, Inflammatory Cytokines and Intestinal Permeability. *Renal failure* 35: 497-503.
23. Alvarez JA, Zughair SM, Law J, Hao L, Wasse H, et al. (2013) Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. *Eur J Clin Nutr* 67: 264-269.
24. Gupta GK, Agrawal T, DeCore MG, Mohiuddin SM, Agrawal DK (2012) Vitamin D Deficiency Induces Cardiac Hypertrophy and Inflammation in Epicardial Adipose Tissue in Hypercholesterolemic Swine. *Experimental and Molecular Pathology* 93: 82-90.
25. Bednarek-Skublewska A, Smoleń A, Jaroszyński A, Załuska W, Ksiazek A (2010) Effects of vitamin D3 on selected biochemical parameters of nutritional status, inflammation and cardiovascular disease in patients undergoing long-term hemodialysis. *Pol Arch Med Wewn* 120: 167-174.
26. Wasse H, Cardarelli F, De Staercke C, Hooper C, Veledar E, et al. (2011) 25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients. *BMC Nephrology* 12: 24.
27. Echida Y, Mochizuki T, Uchida K, Tsuchiya K, Nitta K (2012) Risk Factors for Vitamin D Deficiency in Patients with Chronic Kidney Disease. *Intern Med* 51: 845-850.
28. Duplancic D, Cesarik M, Poljak NK, Radman M, Kovacic V, et al. (2013) The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection. *Clinical Interventions in Aging* 8: 149-156.
29. Izquierdo MJ, Cavia M, Muñoz P, de Francisco AL, Arias M, et al. (2012) Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. *BMC nephrology* 13: 159.

Copyright: © 2016 Ceratto PC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Ceratto PC, Ribeiro MVG, e Silva RCR, e Silva DTR (2016) Implications of Vitamin D Deficiency in Chronic Kidney Disease - A Systematic Review. *Arch Clin Nephrol* 2(1): 008-010.